Principal Investigator
Hadar Lev-Tov
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20250465
Clinical Trial Summary
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
Phase
Phase III
Funding Agency/Sponsor
Industry
Disease
Pediatric Dermatology